From: Evaluation of intravenous voriconazole in patients with compromised renal function
Parameter | Voriconazole | Caspofungin | Fluconazole | p-value for overall difference |
---|---|---|---|---|
n (%) | 19 (14.8) | 55 (43.0) | 54 (42.2) | |
Age, Mean (SD) | 61.7 (13.9) | 63.9 (13.9) | 63.7 (14.7) | 0.83 |
Male, n (%) | 10 (52.6) | 34 (61.8) | 20 (37.0) | 0.03 |
White, n (%) | 17 (89.5) | 43 (78.2) | 49 (90.7) | 0.63 |
Length of treatment (days) | ||||
Mean (SD) | 8.1 (6.3) | 8.6 (5.3) | 9.8 (9.8) | 0.62 |
Median (IQR) | 6.0 (4–12) | 7.0 (5–11) | 8.0 (5–11) | 0.53 |
Min, Max | 2, 29 | 2, 27 | 2, 74 | NS |
Comorbidities: Diabetes mellitus, hypertension or nephropathy, n (%) | 11 (57.9) | 46 (83.6) | 43 (79.6) | 0.06 |
Underlying condition, n (%) | 0.001 | |||
Cancer | 12 (63)* | 7 (13) | 13 (24) | |
HIV | 0 | 0 | 1 | |
ICU | 15 (79) | 31 (56) | 26 (48) | |
Immunosuppression** | 12 (63) | 3 (5) | 12 (22) | |
More than 1 underlying condition | 12 (63) | 9 (16) | 16 (30) | |
Concomitant nephrotoxic agent, n (%) | 14 (73.7) | 31 (56.4) | 27 (50.0) | 0.20 |
Underlying fungal disease, n (%)* | 0.002 | |||
Candida spp. | 5 (55.6) | 43 (93.5) | 39 (92.9) | |
Aspergillus spp. | 4 (44.4) | 3 (6.5) | 3 (7.1) | |
Indication for antifungal therapy, n (%) † | NS | |||
Prophylaxis | 10 (53) | 8 (15) | 5 (9) | |
Empiric | 0 | 1 (2) | 5 (9) | |
Presumed or Confirmed | 9 (47) | 46 (84) | 42 (78) |